Skip to content
Peptides Made Clear
Evidence 3 · Limited or observational human evidenceDevelopment discontinued

ACE-031 Research Protocol & SUBQ Calculator

Experimental compound: ACE-031 development was discontinued after clinical safety signals involving nosebleeds, gum bleeding, and dilated skin blood vessels. Published schedules are shown for research literacy only and are not dosing recommendations.

ACE-031 · Muscle & Recovery · Joints & Tissue Repair

Experimental recombinant ActRIIB-Fc fusion protein; not an approved medication.

Evidence reality check

Studied in people, but not an approved regimen

Development was discontinued after vascular and bleeding-related safety findings.

Published schedules are shown for research literacy only.

Last medically/research reviewed: 2026-09-12

Compare
← 5-Amino-1MQAdamax →

Published schedule explorer

ACE-031 Research Protocol & SUBQ Calculator

Explore published experimental schedules, reconstitution math, administration dates, and post-dose observation periods.

Quick Reference

Compound type
Recombinant ActRIIB–Fc fusion protein
Route studied in humans
Subcutaneous injection
Human evidence
Phase 1 and discontinued Phase 2 research
Published amount
Weight-based, measured in mg/kg
Published frequency
Single dose or once every 2–4 weeks
Half-life
Approximately 10–15 days
Established consumer cycle
None
Established rest/restart period
None
Development status
Discontinued

Choose a Research Model

Published schedules remain labeled as study records. Custom mode performs arithmetic only.

Published DMD clinical-trial schedule—not a recommendation. Published schedules are not recommendations.

Reconstitution calculation

Mathematical research calculation—not administration instruction.

Enter weight, vial strength, and BAC water to see the mathematical results.

Post-dose observation period

No evidence-based ACE-031 rest or restart interval has been established. An observation period is not permission or guidance to begin another cycle.

Why ACE-031 Development Was Discontinued

Clinical safety signals and unresolved systemic risk

  • Nosebleeds
  • Gum bleeding
  • Telangiectasias or visible dilated skin blood vessels
  • Injection-site erythema
  • Potential unintended effects from binding BMP9, BMP10, activins, and other ActRIIB ligands
  • Unknown long-term cardiovascular, vascular, reproductive, and systemic risks

Stop-condition signals reported during development included unexplained bleeding and new dilated skin blood vessels. ACE-031 has no established self-administration protocol.

Evidence Separation

Amounts from different evidence categories are never merged.

Published human research

Phase 1 and discontinued Phase 2

Published animal research

Nonhuman-primate experiment

Community-reported information

No validated pattern

No consistent, clinically validated community protocol was identified. No community mean, median, starting amount, standard amount, or cycle is shown.

Scientific evidence detail and sources
Open Research Modeler

Quick research snapshot

What the evidence currently shows

Evidence strength
Limited or observational human evidence
reported
Human studies
2
reported
Preclinical studies
1
reported
Populations studied
Healthy postmenopausal women, Boys with Duchenne muscular dystrophy, Common marmosets
reported
Routes studied
Subcutaneous
reported
Study schedule
Single dose or once every 2–4 weeks in human research
reported
Study duration
Single dose or 12 weeks between first and final administration
reported
Rest period studied
No evidence-based rest or restart interval has been established.
reported
Last evidence update
2026-09-12
reported

Research evidence, not a prescription

This page summarizes published research and regulatory information. Reported protocols are not personalized recommendations and do not establish safety or suitability for any individual.

Six quick answers

What the record actually establishes

Plain answers

What we know and what we do not

Supported by evidence

Statements backed by verified human or regulatory sources.

  • Not established

Promising but preliminary

Early, limited or preclinical signals only.

  • Not established

Commonly claimed but unproven

Frequently repeated statements that the evidence does not establish.

  • Not established

Evidence-rated claims

Research goals

Research goals awaiting review

No source-verified research goals are published for this compound yet.

Interactive workspace

Reconstitution lab and cycle planner

Final concentration

—

Draw volume

—

U-100 units

—

100 units = 1 mL

Whole amounts per vial

—

Remaining after first draw

—

Vial duration

—

Based on the administrations per week you entered

Vials for the course

—

Bacteriostatic water for the course

—

  • Enter the amount stated on the vial.
  • Enter the volume of bacteriostatic water added, in mL.

Units are calculated from the values you enter. IU and milligram amounts are kept in separate measurement systems because the conversion between them is compound specific.

Missing evidence is not reassurance

Safety matrix

Established risks

Reported in verified human or regulatory sources.

No adverse event was recorded in the sources reviewed. This is not evidence that the compound is without risk.

Possible risks

Reported inconsistently or in limited sources.

No adverse event was recorded in the sources reviewed. This is not evidence that the compound is without risk.

Theoretical risks

Suggested by mechanism only, not observed in studies.

  • Evidence 2 · Animal or laboratory evidence

    Binding BMP9, BMP10, activins, and other ActRIIB ligands may produce unintended vascular effects.

    Reported frequency
    Not established
    unavailable
    Severity
    Not established
    unavailable
    Dose relationship
    Not established
    unavailable
    Route relationship
    Not established
    unavailable
    Population
    All populations
    reported
    Reversibility
    Not established
    unavailable

Unclassified findings

Recorded but not yet assigned a risk tier.

  • Evidence 3 · Limited or observational human evidence

    Nosebleeds, gum bleeding, telangiectasias, and injection-site erythema were reported during clinical development.

    Reported frequency
    Not established
    unavailable
    Severity
    Not established
    unavailable
    Dose relationship
    Not established
    unavailable
    Route relationship
    Not established
    unavailable
    Population
    Human trial participants
    reported
    Reversibility
    Not established
    unavailable
  • Evidence 2 · Animal or laboratory evidence

    Long-term cardiovascular, vascular, reproductive, and systemic risks remain unknown.

    Reported frequency
    Not established
    unavailable
    Severity
    Not established
    unavailable
    Dose relationship
    Not established
    unavailable
    Route relationship
    Not established
    unavailable
    Population
    All populations
    reported
    Reversibility
    Not established
    unavailable

Drug and supplement interactions

No interaction was identified in the current Peptides Made Clear knowledge base. This does not guarantee that an interaction does not exist.

Where the evidence is strong and weak

Research confidence

Confidence ratings pending

Each confidence rating requires a reviewed reason before it can appear here.

Compound-specific answers

Frequently asked questions

FAQs awaiting verified answers

Compound-specific answers appear only after evidence and citation review.

Continue your research

Compare this compoundExplore by research goalOpen full calculator

This page is for educational and research purposes only. It does not diagnose, treat, prescribe or provide individualized medical advice. Investigational status, evidence and regulation can change and differ by jurisdiction. Qualified professional guidance is essential. Information may contain errors despite review. For a possible medical emergency, contact local emergency services.

Report outdated or incorrect information